Not medical advice. Talk to your provider before using any peptide.
Full disclaimerCJC-1295 (No DAC) vs Ipamorelin
Peptide Schedule Research TeamReviewed Apr 202613 Citations
Side-by-side comparison of dosage, benefits, and side effects.
The community figured this one out before the researchers did. CJC-1295 without DAC, also called Mod GRF 1-29 (parent GRF(1-29) CAS 83930-13-6), is a 29-amino-acid GHRH analog modified at four positions to resist enzymatic breakdown. Its closest human data comes from Frohman et al. (1992, PMID 1379256), where hGRF(1-29) injected subcutaneously twice daily normalized GH and IGF-1 in older men. The mechanism is direct. Mod GRF 1-29 binds the GHRH receptor on pituitary somatotroph cells, triggering a cAMP-driven GH release that peaks around 15 to 30 minutes and clears within the hour. That short action window is the entire point. Unlike the DAC version (which circulates for days and produces tonic GH elevation), the no-DAC form preserves your natural pulsatile rhythm. Real-world use centers on the Mod GRF + Ipamorelin stack. Community consensus across hundreds of r/Peptides threads and practitioner networks puts the standard protocol at 100 mcg of each, co-injected subcutaneously once or twice daily on a fasted stomach before bed. Users consistently report improved sleep within the first two weeks, faster recovery by week three, and visible body composition changes by month two. Vendor quality is a known problem; Finnrick Analytics found purity as low as 68.75% across 244 samples from 47 vendors. No FDA-approved form exists, and no Phase I, II, or III trial has been completed for Mod GRF 1-29 specifically.
View full guide →Zero cortisol increase at 200 times the effective GH dose. That single data point from Raun et al. (1998, PMID 9849822) explains why ipamorelin became the default starter peptide for growth hormone optimization. Ipamorelin (molecular weight ~711 Da) is a synthetic pentapeptide and selective GHS-R1a agonist. It binds the ghrelin receptor on pituitary somatotroph cells, producing a GH pulse within 15 to 30 minutes of subcutaneous injection. Human pharmacokinetic modeling by Svensson et al. (1999, PMID 10496658) confirmed a 2-hour half-life, roughly 95% subcutaneous bioavailability, and a dose-response ceiling around 300 to 400 mcg per injection. Going higher doesn't produce a bigger pulse. The real-world use case is straightforward. Most users inject 100 to 300 mcg subcutaneously, one to three times daily on an empty stomach. Nearly everyone stacks it with CJC-1295 (no DAC), also called Mod GRF 1-29, to hit both GHS-R1a and GHRH receptor pathways simultaneously. That dual-pathway approach produces a synergistic GH pulse two to three times larger than either peptide alone. Bedtime dosing is the priority; the fasting window matters because insulin raises somatostatin, which fully blunts the GH response. Community evidence is strong. Hundreds of r/peptides threads (roughly 95,000 subscribers) consistently report improved sleep within one to two weeks, faster recovery by weeks three to four, and gradual body composition changes over six to twelve weeks. The scientific picture is less complete. The only finished human RCT (Phase 2b for postoperative ileus) failed its primary endpoint versus placebo. All efficacy data for anti-aging and body composition applications is community-derived. Preclinical work on bone mineral content (Andersen et al. 1999, PMID 10828840) and cachexia (2024 ferret model, PMID 39043357) looks promising but hasn't been replicated in humans.
View full guide →At a Glance
| Attribute |  CJC-1295 (No DAC) |  Ipamorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| Safety Grade | B | B |
| Half-Life | ~30 min | ~2 hours |
| Route | Subcutaneous | Subcutaneous |
| Vial Sizes | 2mg, 5mg | 2mg, 5mg |
| Beginner Dose | 100mcg Daily | 100mcg Daily |
| Moderate Dose | 100mcg 2x Daily | 200mcg 2x Daily |
| Aggressive Dose | 200mcg 2x Daily | 300mcg 3x Daily |
| Dosing Source | Community | Community |
| Side Effects | The biggest safety concern with CJC-1295 (No DAC) is that zero completed clinical trials exist for this specific compound. Every side effect profile is extrapolated from analog studies and community experience. That context matters for everything below. Facial flushing is the most immediately noticeable effect. It typically hits within 5 to 15 minutes of injection, feels like a warm rush to the face and ears, and resolves within 30 to 60 minutes. This is a vasodilatory response from the GH pulse itself, not an allergic reaction. Community reports treat it as a sign the peptide is active. Reducing the dose lessens the intensity. Headache and dizziness occur in some users, usually during the first week. These tend to be transient and resolve as the body adjusts to regular GH pulses. Injection site redness and irritation are typical of any subcutaneous peptide; rotating sites prevents local tissue issues. Water retention is the side effect that gets the most community attention at higher dose frequencies. GH promotes sodium and water reabsorption. Mild puffiness around the hands and face is common, especially at twice-daily dosing. If retention becomes pronounced (visible edema, tight rings, swollen ankles), reduce frequency before reducing dose. Persistent edema warrants checking IGF-1 levels. Carpal tunnel symptoms (tingling, numbness in the hands, grip weakness) signal excessive GH-mediated fluid retention compressing the median nerve. This is a dose-dependent effect. Reduce dose immediately if it appears. If symptoms persist beyond one week at a lower dose, stop entirely and allow four or more weeks of recovery. GH release antagonizes insulin action. Anyone with diabetes, prediabetes, or insulin resistance should monitor fasting glucose carefully. Teichman et al. (2006, PMID 16352683) documented insulin sensitivity effects with the DAC form; the no-DAC form carries the same mechanistic risk at lower magnitude due to shorter exposure. GH promotes cell proliferation. Active cancer or a history of malignancy is a contraindication. Pregnancy and breastfeeding are absolute contraindications. Untreated hypothyroidism can blunt the GH response entirely and should be addressed before starting. Vendor quality adds an underappreciated risk layer. Finnrick Analytics tested 244 samples from 47 vendors and found purity ranging from 68.75% to 99.95%. Underdosed or degraded product produces unpredictable responses; the no-DAC form (MW approximately 3,367 Da) is sometimes substituted with the DAC form (MW approximately 5,885 Da) by low-quality vendors. When to see a doctor: carpal tunnel symptoms that don't resolve with dose reduction, persistent unexplained edema, fasting glucose above 125 mg/dL, or any new numbness or paresthesia. | The most serious risk with ipamorelin is IGF-1 overshoot. Sustained supraphysiological IGF-1 levels carry a theoretical cancer promotion risk, particularly in anyone with active malignancy or a history of cancer. GH promotes cell proliferation. That's the mechanism behind its benefits and its biggest concern. If IGF-1 climbs above the age-adjusted upper normal range on two consecutive readings, the protocol should stop. Carpal tunnel symptoms (tingling or numbness in the hands) are the clearest signal that GH levels have gone too high. Community reports flag this primarily at the aggressive tier (300 mcg three times daily). This isn't a "push through it" side effect. Tingling means stop immediately, wait at least four weeks, and restart at a lower dose and frequency if appropriate. Water retention is common, especially at twice-daily or three-times-daily dosing. Mild puffiness around the face or ankles is the typical presentation. Reducing injection frequency (not dose) is the first adjustment. Transient headache within 30 to 60 minutes of injection is expected and relates directly to the acute GH pulse. It resolves within hours for most users. Cutting the dose by 25% usually handles persistent headache. Injection-site reactions (mild redness, irritation) are reported frequently in the first two weeks and tend to resolve with consistent site rotation. Abdomen is the preferred injection location. Occasional lightheadedness immediately post-injection is reported but typically mild. Published side effect data in humans is limited. The only completed human RCT (Phase 2b, postoperative ileus, approximately 100 participants) recorded adverse events but focused on GI recovery endpoints rather than the subcutaneous anti-aging use case. Community side-effect reporting across hundreds of threads is remarkably consistent, which provides reasonable confidence in the profile above, but formal incidence rates don't exist for the off-label application. GH release antagonizes insulin action. Fasting glucose should be monitored at baseline, week six, and week twelve. Anyone with uncontrolled diabetes or severe insulin resistance should not use ipamorelin. A fasting glucose above 126 mg/dL means discontinuation. Pregnancy and breastfeeding are contraindicated due to insufficient safety data. GH supplementation can also unmask subclinical hypothyroidism by accelerating T4-to-T3 conversion; thyroid monitoring (TSH, fT3) is recommended at baseline. When to see a doctor: persistent hand tingling or numbness, significant edema, fasting glucose above 126 mg/dL, any visual changes, or symptoms of intracranial hypertension. |
Key Differences
- CJC-1295 is a GHRH analog that boosts the amplitude of natural growth hormone pulses; ipamorelin is a GHRP that triggers a fresh pulse through the ghrelin receptor.
- CJC-1295 (no DAC) has the shorter half-life at roughly 30 minutes; ipamorelin runs around 2 hours. They get dosed together anyway, to stack their different mechanisms.
- Ipamorelin is the cleanest GHRP available. It doesn't raise cortisol, prolactin, or appetite the way GHRP-2 or GHRP-6 do.
- They hit different receptors (GHRH-R vs GHS-R), so their effects add up rather than overlap. That's why most GH protocols run both together.
When to Choose CJC-1295 (No DAC)
- Sustained GH pulse amplification is the goal
- Overall IGF-1 levels need a lift
- You want to pair it with a GHRP for a stronger combined pulse
- Sleep quality and deep sleep improvement is a priority
When to Choose Ipamorelin
- A clean GH secretagogue with minimal side effects is the priority
- Cortisol or prolactin elevation is a concern
- You want to start with a single GH peptide before adding a stack partner
- Fat loss and body composition are the primary goals
Can You Stack CJC-1295 (No DAC) + Ipamorelin?
CJC-1295 + ipamorelin is the most common GH peptide stack. The combination is mechanistically simple. Ipamorelin triggers a GH pulse through the ghrelin receptor. CJC-1295 amplifies the amplitude of that pulse through the GHRH receptor. The two effects add up instead of overlapping. The result is a stronger, cleaner GH release than either peptide alone. Many vendors sell it as a pre-mixed blend.
Dosage Calculators
Or use the universal Peptide Calculator for any peptide.